The Prevention of an Expected Hepatic Flare in HBe negative Patients after Lamivudine Discontinuation

Authors

  • Zahari Krastev Clinic of Gastroenterology, St. Ivan Rilsky University Hospital, Medical University, Sofia, Bulgaria
  • Krasimir Antonov Clinic of Gastroenterology, St. Ivan Rilsky University Hospital, Medical University, Sofia, Bulgaria
  • Deian T. Jelev Clinic of Gastroenterology, St. Ivan Rilsky University Hospital, Medical University, Sofia, Bulgaria

Keywords:

HBV hepatitis, lamivudine

Abstract

The treatment with lamivudine leads to drug resistant mutations in 19 to 70% cases after 1- and 5-year therapy, respectively, associated with the risk of severe rebound of liver disease with alaninaminotransferase flare. In this situation, adefovir should be added, but this drug is not available in every country. We report three cases where we avoided the expected hepatic flare-ups by using IFN and isoprinosine. Based on this empirical experience, we suggest that the new drug has to be administered one month before discontinuation of lamivudine. Prospective trials are mandatory.

Downloads

Published

2006-12-01

How to Cite

1.
Krastev Z, Antonov K, Jelev DT. The Prevention of an Expected Hepatic Flare in HBe negative Patients after Lamivudine Discontinuation. JGLD [Internet]. 2006 Dec. 1 [cited 2025 Jul. 1];15(4):389-91. Available from: https://www.jgld.ro/jgld/index.php/jgld/article/view/2006.4.11

Issue

Vol. 15 No. 4: December 2006

Section

Case Reports